Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025-04 · 23 (4) · 441-445
DOI: 10.1111/ddg.15638 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 13.02.2025. Verfasst von Jasper N Pruessmann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Luebeck, University Hospital Schleswig-Holstein, Luebeck, Germany. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Autoimmune Diseases, Skin Diseases, Vesiculobullous, Pemphigoid, Bullous. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune checkpoint receptors and ligands such as cytotoxic T lymphocyte antigen‐4 (CTLA‐4), programmed death‐1 (PD‐1) and ligand‐1 (PD‐L1) are widely expressed on immune and non‐immune cells and fine tune the activation level of immune cells, thus, enabling, preventing, or terminating immune responses. Blockade of CTLA‐4, PD‐1 or PD‐L1 by checkpoint inhibitors (CIs), unleashing immune responses, has become a mainstay in the treatment of diverse types of cancer. The induction of autoinflammatory, yet unspecific tissue damage in diverse organs is called an immune related adverse event (irAE), a class side‐effect of CIs and may require the discontinuation of immunotherapy. Among frequent skin rashes, CIs targeting the PD‐L1/PD‐1 axis can elicit the IgG autoantibody‐ and granulocyte‐driven bullous pemphigoid (BP) in about 0.3% to 0.6% of treated patients. Pathogenesis of BP requires a complex cellular inflammatory response after anti‐BP180 autoantibody binding to the dermal epidermal junction. The prevalence of autoantibodies against BP180 in healthy blood donors of approximately 0.52% equals the prevalence of irBP among treated cancer patients, underlining the potential relevance of the PD‐1 mediated regulation of tissue inflammation for spontaneous BP. If skin rashes appear during CI therapy, biopsies should be taken and examined by histopathological and direct immunofluorescence microscopy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Luebeck, University Hospital Schleswig-Holstein, Luebeck, Germany.
ORCID-Profile: Jasper N Pruessmann
Zitieren
APA
Pruessmann, J. N., Pruessmann, W., & Sadik, C. D. (2025). Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 23(4), 441-445. https://doi.org/10.1111/ddg.15638
Vancouver
Pruessmann JN, Pruessmann W, Sadik CD. Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025;23(4):441-445. doi:10.1111/ddg.15638
BibTeX
@article{Pruessmann2025,
author = {Pruessmann, Jasper N and Pruessmann, Wiebke and Sadik, Christian D},
title = {Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
volume = {23},
number = {4},
pages = {441--445},
doi = {10.1111/ddg.15638}
}
EUVIMED